Integrating New Agents to Optimize Multiple Myeloma Care: Expert Guidance for the Practicing Clinician

Review key data on new agents for multiple myeloma with these downloadable slides and on-demand Webcast, developed by Melissa Alsina, MD, and Suzanne Lentzsch, MD, PhD.
Melissa Alsina, MD
Program Director
Suzanne Lentzsch, MD, PhD
Program Director
person default
Ajai Chari, MD
Raymond L. Comenzo, MD
Jonathan L. Kaufman, MD
Amrita Krishnan, MD, FACP
person default
Elisabet E. Manasanch, MD

Downloadable Slideset

In this downloadable slideset, Melissa Alsina, MD, and Suzanne Lentzsch, MD, PhD, discuss the most recent clinical data for optimizing management of patients with multiple myeloma.

Released: August 18, 2017

On-Demand Webcast

In this archived Webcast from the 2017 CCO Multiple Myeloma Local Live meeting series, Raymond L. Comenzo, MD, provides expert perspective on integrating new agents and approaches into the treatment of patients with multiple myeloma.

Raymond L. Comenzo, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.8 Nursing contact hours Pharmacists: 0.75 contact hours (0.08 CEUs) Released: November 29, 2017 Expiration: November 28, 2018

FAQ Module

Expert answers to frequently asked questions about new agents for the treatment of multiple myeloma, including recently approved therapies and those on the horizon with the potential to change clinical practice.

Melissa Alsina, MD
Program Director
Suzanne Lentzsch, MD, PhD
Program Director
person default Ajai Chari, MD Raymond L. Comenzo, MD Jonathan L. Kaufman, MD Amrita Krishnan, MD, FACP person default Elisabet E. Manasanch, MD
Released: March 9, 2018
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
Celgene Corporation
Karyopharm Therapeutics
Takeda Oncology

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?